2. Academic Validation
  3. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)

Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)

  • J Med Chem. 2015 Aug 27;58(16):6653-64. doi: 10.1021/acs.jmedchem.5b00892.
John A Christopher 1,  Sarah J Aves 1,  Kirstie A Bennett 1,  Andrew S Doré 1,  James C Errey 1,  Ali Jazayeri 1,  Fiona H Marshall 1,  Krzysztof Okrasa 1,  Maria J Serrano-Vega 1,  Benjamin G Tehan 1,  Giselle R Wiggin 1,  Miles Congreve 1
Affiliations

Affiliation

  • 1 Heptares Therapeutics Ltd. , BioPark, Welwyn Garden City, Hertfordshire AL7 3AX, U.K.
PMID: 26225459 DOI: 10.1021/acs.jmedchem.5b00892
Abstract

Fragment screening of a thermostabilized mGlu5 receptor using a high-concentration radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit 5. Subsequent optimization using structure-based drug discovery methods led to the selection of 25, HTL14242, as an advanced lead compound for further development. Structures of the stabilized mGlu5 receptor complexed with 25 and another molecule in the series, 14, were determined at resolutions of 2.6 and 3.1 Å, respectively.

Figures
Products